We are live on ! Find out more
RGLS

Regulus Therapeutics
RGLS

Delisted

RGLS was delisted on the 24th of June, 2025.

Back to rankings

46 hedge funds and large institutions have $34.2M invested in Regulus Therapeutics in 2018 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% less ownership

Funds ownership: 0.43% → 0.41% (-0.01%)

8% less funds holding

Funds holding: 50 → 46 (-4)

10% less capital invested

Capital invested by funds: $38.1M → $34.2M (-$3.9M)

40% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 10

45% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 11

Holders
46
Holders Change
-4
Holders Change %
-8%
% of All Funds
1.05%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
6
Reduced
11
Closed
10
Calls
$8K
Puts
–
Net Calls
+$8K
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Ascend Capital
California
+$46K
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$37.2K
3
Invesco
Invesco
Georgia
+$14K
4
Goldman Sachs
Goldman Sachs
New York
+$11.5K
5
BAS
Brown Advisory Securities
Maryland
+$10.3K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$199K
2
DZ Bank
DZ Bank
Germany
-$147K
3
BlackRock
BlackRock
New York
-$135K
4
ARTA
A.R.T. Advisors
New York
-$91.7K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$89.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$10.3M +$37.2K +450 +0.3%
BI
2
BVF Inc
California
$9.02M -$199K -2,409 -2%
NMC
3
NEA Management Company
Maryland
$7.24M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.75M -$89.1K -1,077 -5%
BC
5
Boxer Capital
California
$1.12M – – –
SDIC
6
South Dakota Investment Council
South Dakota
$1.11M -$64.2K -776 -5%
AC
7
Ascend Capital
California
$705K +$46K +556 +7%
Point72 Asset Management
8
Point72 Asset Management
Connecticut
$486K – – –
BlackRock
9
BlackRock
New York
$386K -$135K -1,629 -25%
CS
10
Candriam SCA
Luxembourg
$330K – – –
RPAM
11
Rhenman & Partners Asset Management
Sweden
$325K – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$319K – – –
Wells Fargo
13
Wells Fargo
California
$248K -$5.87K -71 -2%
Northern Trust
14
Northern Trust
Illinois
$124K – – –
California Public Employees Retirement System
15
California Public Employees Retirement System
California
$117K – – –
Royal Bank of Canada
16
Royal Bank of Canada
Ontario, Canada
$99K +$2.48K +30 +2%
DS
17
DRW Securities
Illinois
$89K – – –
Renaissance Technologies
18
Renaissance Technologies
New York
$79K -$6.21K -75 -7%
PAM
19
Panagora Asset Management
Massachusetts
$56K +$3.64K +44 +7%
WS
20
Wedbush Securities
California
$54K -$48.3K -584 -46%
ARTA
21
A.R.T. Advisors
New York
$24K -$91.7K -1,108 -78%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$23K -$22.9K -277 -49%
USAA
23
United Services Automobile Association
Texas
$22K – – –
Millennium Management
24
Millennium Management
New York
$16K -$59.2K -715 -78%
State Street
25
State Street
Massachusetts
$16K -$21.2K -256 -54%
1
2 3

RGLS Hedge Fund Activity: Q2 2018 in Review

46 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q2 2018, worth a combined $34.2M — down 10% from $38.1M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of RGLS and 6 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 6 added.

The largest buyer was Ascend Capital, adding an estimated $46K. The largest seller was BVF Inc, cutting an estimated $199K.

  • 46 institutional investors held Regulus Therapeutics (RGLS) as of Q2 2018, down from 50 in Q1 2018.
  • Funds reported $34.2M of Regulus Therapeutics stock for Q2 2018, down 10% quarter-over-quarter.
  • 6 funds opened new Regulus Therapeutics positions in Q2 2018 and 10 closed out, a net change of -4 holders.
  • The largest Regulus Therapeutics buyer in Q2 2018 was Ascend Capital, an estimated $46K added.
  • The largest Regulus Therapeutics seller in Q2 2018 was BVF Inc, an estimated $199K sold.

Based on aggregated 13F filings for Q2 2018.